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Purpose. We sought to evaluate our experience using yttrium-90 (90Y) resin microsphere hepatic radioembolization as salvage
therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with
unresectable mCRC who were treated with 90Y after failing ﬁrst and second line systemic chemotherapy. Demographics, treatment
dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y
treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous
liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was
seen in 77% of patients. Overall median survival from the time of ﬁrst 90Y treatment was 10.2 months (95%CI = 7.5–13.0). The
absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0
months (95%CI = 6.4–27.6), compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95%CI
= 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who
have failed ﬁrst and second line chemotherapy and have adequate liver function and performance status.
1.Introduction
Colorectal carcinoma, estimated to occur at an incidence of
148,810 cases in the USA in 2008 causing 49,960deaths, is
the major contributor of metastatic liver tumors [1]. Hepatic
metastases are present in 15–25% of patients at presentation,
and an additional 25–50% will develop liver metastases
within 3years following resection of the primary tumor
[2, 3]. In approximately half of these patients, metastatic
disease is conﬁned to the liver, and 20% of all patients who
die of metastatic colorectal cancer have metastases limited
to the liver. Hepatic resection for colorectal liver metastases
has become the standard of care, and currently remains
the only potentially curative therapy. Unfortunately, curative
resection is possible in less than 25% of those patients with
metastases to the liver.
Currently, the armamentarium against unresectable liver
tumors is composed of a number of liver-directed therapies
aimed at reducing the hepatic tumor burden. Yttrium-
90 (90Y) bound microspheres are an emerging tool for
the treatment of primary and metastatic liver cancer that
has had promising results. The use of whole-liver external
beam radiation therapy for hepatic malignancies has been
limited secondary to the relative intolerance of normal liver
parenchyma to the dose of radiation necessary to have a
response in neoplastic tissue. It has long been known that
hepatic parenchyma is largely supplied by the portal system,
but hepatic neoplasms are primarily supplied by the arterial
system [4]. Therefore, therapy directed into the hepatic
arterial system is preferentially targeted to the neoplasm
with relative sparing of the normal parenchyma allowing for
substantially higher doses of radiation or chemotherapeutic
agents to be administered to the liver tumor tissue. Selective
internal radiation therapy (SIRT), using 90Y microspheres
delivered into the hepatic arterial system, takes advantage
of the heterogeneity in blood supply between neoplastic2 International Journal of Surgical Oncology
and parenchymal tissue allowing for localized high-dose
radiation therapy to be delivered to intrahepatic tumors.
In addition to providing localized radiation therapy, the
microspheres may also serve to provide an embolic compo-
nent to the therapy leading to tumor ischemia. Pathologic
examinationofexplantshasshownthat 90Ymicrospheresare
dispersed preferentially to the periphery of neoplastic tissue
[5].
90Y is a pure beta-emitting isotope with a maximal
energy of 2.27MeV and average energy of 0.94MeV. The
maximum range of emission in tissue is 11mm with mean
range of 2.5mm, allowing tissue only in close proximity to
the embolized microspheres to be treated. The half-life of
90Y is 64.1hours with 94% of radiation delivered in 11days
[6]. Currently in the U.S. market, there are two commercially
available microspheres that are irreversibly bound to90Y; the
microspheres are composed of either resin or glass. Both are
biocompatible beads with an average diameter of 20–40µm
that are permanently implanted in the liver via emboliza-
tion through the hepatic artery. The resin microspheres
receivedU.S.FoodandDrugAdministration(FDA)approval
in 2002 for unresectable liver metastases from primary
colorectal cancer with adjuvant intrahepatic chemotherapy
using ﬂoxuridine (FUDR). Glass microspheres were granted
humanitarian device exemption (HDE) in 1999 for radiation
treatment or as a neoadjuvant to surgery or transplantation
inpatientswithunresectablehepatocellularcarcinoma[6,7].
Several studies have previously shown that 90Ym i c r o -
sphere radioembolization produce adequate response rates
in colorectal cancer liver metastases with an acceptable
toxicity proﬁle [8–19]. However, many of these earlier expe-
riences with 90Y occurred prior to widespread availability
of the newer chemotherapeutic agents and regimens. With
the addition of biological agents, such as bevacizumab
and cetuximab, to chemotherapy regimens incorporating
irinotecan and oxaliplatin the median survival rates and
responseratesimprovedinpatientswithmCRC[20,21].The
eﬀectiveness of 90Y in patients after failing the latest systemic
chemotherapy has yet to be fully evaluated. We sought
to retrospectively evaluate our single-institution experience
treating patients with liver-dominant mCRC in the salvage
setting with 90Y resin microsphere radioembolization.
2.MaterialandMethods
2.1. Patient Selection, Workup, and Treatment. All patients
in this series were treated consecutively with 90Y radioem-
bolization between August 2002 and May 2008 for liver-
dominant mCRC at the University of Pittsburgh Medical
Center. Patients eligible to receive 90Y were not candidates
for hepatic resection or ablation, had progressive disease
after ﬁrst and second line chemotherapy, had Eastern
Conference Oncology Group (ECOG) performance status of
0-1, had adequate hepatic function (serum total bilirubin
<2.0), and had adequate renal and hematologic function.
Progressive disease was deﬁned as increase in tumor burden
byradiographicvolumeornumberofmetastases.Bothintra-
and extrahepatic tumors were evaluated for progression,
although intrahepatic progression was the determinate for
90Y treatment candidacy. Patients that were considered for
90Y treatment had either exhausted or refused standard
chemotherapy regimens. Patients with extrahepatic metas-
tases were treated only if the tumor burden outside the liver
was <10% of total tumor burden and chemotherapy options
were not available. Data was recorded via an Institutional
Review Board approved protocol.
The technical details and dosimetry of the process have
previously been described [22, 23]. However, we chose to
use a modiﬁed partition model for the calculation of the
90Y microsphere activity to be administered to the patient,
similar to the methodology used for 90Y glass microspheres.
The prescribed activity was calculated to deliver 50Gy to
the targeted liver tissue, assuming a uniform distribution of
microspheres in the normal liver parenchyma and tumors,
with no correction for any activity shunted to the lungs:
Activity

GBq

= Dose

Gy

×Mass

kg

/50. (1)
The liver mass is determined from the target liver volume
obtained from CT(cm3) × 0.00103kg/cm3. This methodol-
ogy was thought to more accurately estimate the radiation
dose to the normal liver parenchyma for lobar and segmental
treatments than the BSA or Empirical dosing method-
ologies. However, because of the nonuniform distribution
of microspheres in the tumor and normal liver tissue, a
proportionally larger radiation dose will be delivered to the
tumor tissue and less to the normal liver [22, 23]. Only resin
microspheres were used to treat patients in this study. Prior
to 90Y administration, all patients had a selective visceral
angiogram, technetium-99m-labeled macroaggregated albu-
min (99mTc-MAA) study, and a baseline CT or PET/CT.
The selective visceral angiogram allows for deﬁnitive
assessmentofthearterialanatomyandpossibleembolization
of vessels that may lead to extrahepatic 90Ye x p o s u r e .
The 99mTc-MAA study allows pulmonary shunting to be
evaluated. The use of 90Y radioembolization is avoided
if there is any uncorrectable extrahepatic shunting to the
gastrointestinal tract, or >0.6GBq (corresponding to a lung
dose of 30Gy) is shunted to the lungs.
90Y was administered via unilobar treatments. When
bilobar disease was present, the lobes were treated sequen-
tially with approximately a one-month interval. Some
patients had multiple treatments to the same lobe. The
determination to treat the same lobe repetitively was made
by evaluating the performance status, liver function, and
extent of extrahepatic disease. However, the determination
to retreat patients was based solely on progression of disease
as assessed via CT. Early in our experience 17 patients
had received ﬂoxuridine (FUDR) (5mg/kg) infused via the
hepatic artery just prior to instillation of 90Y microspheres.
This was stopped due to concerns of FUDR-induced biliary
sclerosis seen in prior hepatic artery infusion pump therapy
cases, but not in these particular patients. After treatment,
patients were observed in the hospital overnight and patients
were discharged home the next day with oral narcotics and
antiemetics.International Journal of Surgical Oncology 3
2.2. Patient Followup and Evaluation. Toxicity data was
reviewed from hospital records and laboratory data. Labo-
ratory data was assessed using National Cancer Institute’s
Common Terminology Criteria for Adverse Events v3.0.
Patients were followed with weekly laboratory data and
routine oﬃce followup. A CEA response was deﬁned as a
≥50% reduction in posttreatment value when compared to
baseline measurements at the time of initial 90Yt r e a t m e n t .
Followup imaging was performed every 3months using
eithertriphasicCTsorPET/CTs.Theradiologicresponsewas
graded using the RECIST criteria [24]. In brief, the sum of
the longest diameter of the ﬁve largest hepatic lesions was
measured on baseline and follow-up imaging. A complete
response was deﬁned as disappearance of all target lesions,
partial response was at least a 30% decrease in the overall
diameter, and progressive disease was at least a 20% increase
in diameter. Stable disease were those cases between partial
response and progressive disease. Follow-up imaging from
30–180days after the initial treatment were used for data
analysis.
2.3. Statistics. Data were entered and veriﬁed using the
Statistical Package for Social Sciences (SPSS version 16) for
Windows (SPSS Inc., Chicago, IL). Kaplan-Meier survival
analyses using log-rank methods were used to estimate
overall survival of the entire sample as well as to test
diﬀerences in survival between groups. Mean and median
survival was reported (with 95% conﬁdence intervals).
Variables studied in the univariate analysis included gender,
age (>50 and <50years), presence of extrahepatic disease,
prior liver-directed therapy, chemotherapy failure, number
of treatments (<2o r≥2), whether FUDR was given concur-
rently with90Y, CEA response, radiologic response, and total
amount of radiation delivered prior to embolization (< or
≥80% of prescribed dose). Survival was calculated from the
time of ﬁrst 90Y treatment to the time of death.
3. Results
3.1. Demographics, Treatment Regimen, and Tumor Char-
acteristics. Fifty-one patients were treated a total of 90
times with 90Y microspheres. The median age of patients
treated was 64years (range 37–83) (Table 1). All patients
had undergone extensive chemotherapy with 33 (73%)
patients receiving either bevacizumab or cetuximab, and 9
(20%) patients receiving both. Fourteen (31%) patients had
received prior capecitabine. Previous liver-directed therapy
was performed in 16 (31%) patients. Liver-directed treat-
ment included radiofrequency ablation in 11 patients, and
previous hepatic artery chemoinfusion in 5 patients. Liver
resections were performed in 12 (23%) patients prior to 90Y
therapy.
Although all patients had liver-dominant metastatic
disease, a substantial number had radiographically demon-
strable extrahepatic metastases. The presence of extrahepatic
disease was known in 28 (58%) patients at the time of
90Y treatment. The sites of extrahepatic disease included
pulmonary nodules (n = 14), portocaval or retroperitoneal
Table 1: Patient characteristics of those treated with 90Yf o rl i v e r -
dominant metastatic colorectal cancer.
n (%) Median Range
Age (years) 64 37–83
Male 35 (68.6)
Female 16 (31.4)
Time from diagnosis
of metastases to 1st
Rx (months)
23.2 1.3–99.9
Extrahepatic disease
present 28 (58.3)
Pulmonary nodules
present 14 (28.5)
Previous
liver-directed therapy 16 (31.4)
Previous liver
resection 12 (23.5)
Previous RFA 11 (21.5)
Previous hepatic
artery chemoinfusion 5 (9.8)
Failed either
bevacizumab or
cetuximab∗
33 (73.3)
Failed both
bevacizumab or
cetuximab
9 (20.0)
Failed capecitabine 14 (31.1)
∗Those receiving both bevacizumab and cetuximab also included.
lymphadenopathy (n = 13), anastomotic recurrence or
unresected primary colorectal tumor (n = 5), peritoneal
disease (n = 4), bone metastases (n = 1), and adrenal
metastases (n = 1).
The median time from the diagnosis of hepatic metas-
tases to the ﬁrst 90Y treatment was 23.2 months (range, 1.3–
99.9 months). One treatment was administered to 20 (39%)
patients, 2 treatments to 27 (53%) patients, and 4 treatments
to 4 (8%) patients (Table 2). The median lung shunt was
3.3% (range, 0.4–11.5%). No patients were excluded from
treatment due to either an unacceptable level of pulmonary
shunting or uncorrectable shunting to the extrahepatic
gastrointestinal tract. The median dose administered to the
targetlobepertreatmentwas44.4Gy.Themedianprescribed
activity of 90Y administered was 1.10GBq versus the median
activityactuallydeliveredof0.89GBq.FUDRwasgivenprior
to 90Y in 17 (33%) patients, all of which were treated at the
start of the study period. In 67 (74%) treatments ≥80% of
prescribed dose was administered. All of those with <80% of
the prescribed dose received had the treatment terminated
due to the stagnation of ﬂow secondary to the embolic
process. There was no survival diﬀerences found when the
actual dose administered was analyzed. However, patients
who had one or more of the treatments terminated before
the target dose was reached had a trend (P = .12) towards
improved survival. Those who had stagnation of ﬂow prior
to reaching the target dose had a median survival of 19.1
months (95% CI = 8.7–29.5) compared to 6.7 months (95%4 International Journal of Surgical Oncology
Table 2: Treatment characteristics: Floxuridine (FUDR) was given
with 90Y in some of our earlier patients. FUDR (5mg/kg) was given
just prior to administration of the 90Y microspheres.
n (%) Median Range
Total number of
treatments 90
Patients with 1
treatment 20 (39.2)
Patients with 2
treatments 27 (52.9)
Patients with 4
treatments 4 (7.8)
Radiation dose to
target tissue per
treatment (Gy)
44.4 12.9–67.2
Radiation activity per
treatment (GBq) 0.89 0.16–2.20
FUDR with 90Y∗
Yes 17 (33.3)
No 34 (66.7)
Lung shunt (%) 3.3 0.4–11.5
Treatments
terminated early due
to embolic process
40 (44.4)
Treatments with
≥80% of prescribed
dose administered
67 (74.4)
∗Those who had prior hepatic artery chemoinfusion separate from the time
of 90Y administration are not included in this group.
Cl = 2.3–11.0). The median percentage of the prescribed
dose administered in all treatments was 92%. There was
no relationship between premature embolization during
treatment and concurrent administration of FUDR.
3.2. CEA Response. In 41 patients, serial CEA levels were
available for review. A CEA response (≥50% decreases in
CEA from baseline) was seen in 17 (41%) patients (Table 3).
For those who had a CEA response, the median value was
28.5% (range 1–42%) of the baseline before 90Yv a l u e .T h e
CEA nadir was measured at a median of 62 (range 25–
139)days after 90Yt r e a t m e n t .
3.3. Radiologic Response. Although all patients had baseline
and follow-up imaging obtained, only 31 patients had
imaging available for review. This is a reﬂection of our
tertiarycarecenterandmanypatientsreceivedscanscloserto
home, and these were not available for retrospective review.
Extensive eﬀorts were undertaken to obtain imaging that
patients received outside institutions but many radiologic
studies were not available for retrospective interpretation.
Imaging was evaluated for a response to treatments using the
RECIST criteria reviewing CT scans from 1–6months after
treatment. Although, many patients had PET/CT available
towards the end of the series they were not obtained
consistently enough for analysis in patients early in the
Table 3: Clinical endpoints: survival, biochemical, and radiologic
response. Survival analyses to compare whether survival advantage
was associated with studied variables was performed using log-rank
analysis.
n (%) Median survival
(months) 95% CI1
Died during
follow-up 38 (74.5)
Overall survival
(months) 10.2 7.5–13.0
Gender 51 (100) P = .64
M 35 (68.6) 10.6 3.4–17.8
F 16 (31.4) 10.2 0.0–22.0
Age 51 (100) P = .18
<50 10 (20) 5.3 0.8–9.8
>50 41 (80) 8.2 1.8–19.4
FUDR given with 90Y P = .72
Yes 17 (33.3) 17.0 6.7–27.3
No 34 (66.7) 8.2 4.2–12.3
Extrahepatic disease
present 48 (100) P = .07
Yes 28 (58.3) 6.7 2.7–10.6
No 20 (41.7) 17.0 6.4–27.6
CEA response2 41 (100) P = .36
Yes 17 (41.5) 19.1 6.3–31.9
No 24 (42.9) 9.3 6.0–12.7
Radiographic
Response3 31 (100) P = .21
Progressive Disease 7 (22.6) 13.6 7.4–19.8
Stable Disease 20 (64.5) 9.3 6.9–11.8
Partial Response 4 (12.9) 21.5 13.7–29.1
195% Conﬁdence interval.
2CEA response deﬁned as a reduction in CEA ≥50% of pretreatment value.
3RECIST criteria used to compare baseline measurement just prior to 1st
treatment with radiologic response during 1–6months follow-up imaging.
series. No patients had a complete radiologic response. A
partial response (PR) was observed in 4 (13%) patients,
stable disease was seen in 20 (64%), and progressive disease
(PD) in 7 (23%). Of the 7 patients that had PD during the
1–6months follow-up period, 3 patients had met criteria
within 60days, 3 had developed PD from 61–120days, and
1 after 121days. Of the 4patients with PR, 2 had met criteria
within 60days and 2 within 61–120days.
3.4. Survival Analysis. Survival data was acquired from the
electronic medical record and a search of the Social Security
Death Index. Thirty-eight (74%) patients died during the
follow-up period. The median survival with 95% conﬁdence
interval and P-values were calculated for several variables
to identify diﬀerences in survival between groups. The
variables for the univariate analyses included gender, age,
presence of extrahepatic disease, prior liver-directed therapy,
chemotherapeutic agents failed, number of treatments (< orInternational Journal of Surgical Oncology 5
≥2), concurrent administration of FUDR, CEA response,
radiologic response, and early termination due to embolic
process.Ofthetestedvariables,theonlyvariablethatshowed
a signiﬁcant diﬀerence in survival was the use of cetuximab
prior to 90Y treatments.
The overall median survival was 10.2months (95%
CI = 7.5–13.0) for the entire cohort. The overall mean
survivalwas14.4months (95%CI = 10.6–18.1). TheKaplan-
Meier survival curve including all treated patients is shown
in Figure 2. When the presence or lack of extrahepatic
disease was analyzed for an association with survival, there
was a trend toward improved survival in the absence of
extrahepatic disease. The median survival was 6.7months
with extrahepatic disease (95% CI = 2.7–10.6) compared to
17.0months for those without extrahepatic disease (95% CI
= 6.4–27.6) (Figure 1). Those who had received cetuximab
had a signiﬁcantly decreased median survival (P = .001)
(5.1months; 95% CI = 2.6–7.5) compared to patients that
had not received cetuximab prior to 90Y (18.3months; 95%
CI = 6.5–30.0). A signiﬁcant survival diﬀerence was also
observed in those that had previously failed cetuximab and
bevacizumab, but not those who failed only bevacizumab
(Table 4). Although a larger proportion of patients received
biological agents during the ﬁnal years of the study period,
analysis comparing the era of 2002–2004 versus 2005–2008
revealed no signiﬁcant diﬀerence in survival between the two
eras.
CEA response was not associated with a signiﬁcant
improvement in survival (Figure 3). Those with a CEA
decrease of ≥50% from baseline had a 19.1-month (95%
CI = 6.4–31.9) median survival compared to 9.3months
(95% CI = 6.0–12.7) in those with less than a 50% decrease
in CEA. When a radiologic response was analyzed for a
survival advantage, there was not a signiﬁcant association
with survival observed (P = .22). Patients with a partial
response had the longest median survival (21.5months;
95% CI = 13.8–29.2) when compared to those who had
progressive disease (13.6months; 95% CI = 7.4–19.8) and
those who had a stable radiological response (9.3months;
95% CI = 6.9–11.8months). The unexpected results of a
longer median survival in those with progressive disease
compared to stable disease is likely due to the small sample
size and lack of events per group (i.e., 43% censored in
progressive disease).
3.5. Safety and Toxicity. Patient medical records were
carefully reviewed to investigate patient complaints after
treatment. The clinical toxicity proﬁle was acceptable with
fatigue,abdominalpain,andnauseabeingthemostcommon
subjective complaints documented; occurring in 22, 16,
and 12% of patients, respectively. Complaints were minor,
grade 1 or 2, and self-limiting generally resolving within
o n et ot w ow e e k sa f t e rt r e a t m e n t .T h r e ep a t i e n t sr e q u i r e d
hospitalreadmissionwithin30days.Reasonsforreadmission
included an upper GI bleed related to esophageal varices
4days after treatment, unresolved abdominal pain and need
for intravenous narcotics on postprocedure day 1, and the
development of symptomatic brain metastases. One patient
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Figure 1: Kaplan-Meier survival curve comparing those with
extrahepatic disease at the time of treatment versus those with
disease localized to liver. The estimated median survival was
17.0months for those without extrahepatic disease compared to
6.7months. This diﬀerence was found not to be signiﬁcant when
using log-rank analysis, P-value of .07.
Table 4: Survival analysis of those who had received bevacizumab
and/or cetuximab prior to treatment with 90Y.
n (%) Median Survival
(months) 95% CI1
Failed cetuximab 44 (100) P = .001
Yes 16 (36.4) 5.1 2.6–7.5
No 28 (63.6) 18.3 6.5–30.0
Failed bevacizumab 44 (100) P = .36
Yes 17 (38.6) 8.2 5.0–11.4
No 27 (61.4) 17.0 6.7–27.3
Failed both
bevacizumab and
cetuximab
44 (100) P = .001
Yes 9 (20) 5.2 2.9–7.4
No 35 (80) 13.6 4.9–22.2
195% Conﬁdence interval.
developed a complication at the time of the procedure
developing ventricular tachycardia requiring ACLS and sub-
sequentemergentcardiaccatheterization.Theposttreatment
hepatic toxicity was assessed and found to be relatively mild.
No patients had fulminant hepatic failure after treatment.
Serial posttreatment bilirubin levels were available for review
in 49 patients. Of the 47 patients who had a normal starting6 International Journal of Surgical Oncology
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Figure 2: Kaplan-Meier survival curve for all patients (n = 51)
treated with 90Y radioembolization. Survival was calculated from
time of the ﬁrst treatment with90Y. Median survival was estimated
tobe10.2months.The95%conﬁdence-intervalis7.5–13.0months.
bilirubin levels, a grade 2bilirubin toxicity was seen in 5
patients acutely (0–30days) and 4 patients late (31–90days).
Late grade 3 or 4 toxicity was seen in two patients. The grade
4 toxicity was related to a biliary stricture and resolved with
ERCP and stenting. No patients developed posttreatment
gastric or duodenal ulceration, although all patients were
placed on proton pump inhibitors prophylactically.
4. Discussion
Although the survival of patients with mCRC has been
substantially extended with modern chemotherapy, the
eventual progression of disease without a surgical cure is
inevitable. Unfortunately, a surgical cure is only a viable
option in the minority of patients. In this retrospective study
we evaluated the eﬃcacy and safety of using 90Yh e p a t i c
radioembolization in the salvage setting for advanced liver-
dominant mCRC. Our cohort of patients consisted of a
group that was highly pretreated with the current, most
eﬀective chemotherapeutic regimens. The median and mean
survival of 10.2 and 14.4months, respectively, after failure of
all current treatment options is notable. The median survival
is similar to that previously reported by others. Kennedy
et al. had previously published their series of 208 patients
treated with either whole liver or lobar 90Y for salvage
therapy of unresectable mCRC. The median survival in this
study was 10.5months for those with treatment response
and 4.5months in those without a response to treatment
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Figure 3: Kaplan-Meier survival curve comparing those with CEA
response,asindicatedbyadecreaseof ≥50%frombaseline,tothose
who did not have a CEA response posttreatment. The estimated
median survival was 19.1months for those with a CEA response
compared to 9.3months. This diﬀerence was not found to be
signiﬁcant when using log-rank analysis P-value of .36.
that received mainly whole-liver 90Y that for liver-dominant
mCRC with a median survival 10.5months. One notable
diﬀerence between the cohort reported here and that of
Jakobs et al. is that in this cohort the presence of extrahepatic
disease was 58.3% versus 17%, possibly signifying that our
patients had more advanced disease. Sato et al. have also
reported their two institution experiences of 137 patients
withanassortmentofprimarymalignanciestreatedwith 90Y.
Theircohortalsocontained51patientswithmCRC,andthey
reported a median survival of 15.2months in their subgroup
analysis of colorectal cancer patients [15, 19].
There was signiﬁcantly decreased survival observed in
those who had previously failed cetuximab or both cetux-
imab and bevacizumab. A trend in decreased survival was
seen in those who had previously failed bevacizumab. This
result seems to suggest that beneﬁt may be more limited
in those who had previously failed biological chemother-
apeutics. However, further validation of these ﬁndings is
needed. Although unclear at this point, possible reasons for
this diﬀerence could be that more aggressive tumor biology
wasselectedorthatpatientsweretreatedlaterintheirdisease
course.
Surprisingly patients who had one or more of their treat-
ments terminated with <80% of the prescribed dose admin-
istered had a trend towards improved survival. There isInternational Journal of Surgical Oncology 7
likely a range of eﬀective dose of 90Y that elicits a tumor
response, with patients who receive less than the prescribed
dose also demonstrating a response to treatment most likely
related to the completeness of the embolization. However,
this observation requires further evaluation.
A trend towards improved survival was seen in those
without extrahepatic disease at the time of treatment when
compared to those with extrahepatic disease. The median
survival was 17.0months versus 6.7months. Although this
diﬀerence was not signiﬁcant, our survival is comparable
to the median survival of 17.5months without extrahepatic
disease and 6.9months with extrahepatic disease that was
previously reported [25]. The treatment of patients with
widespreadsystemicdiseasehasbeenanexclusioncriteriafor
most treatments using locoregional therapies. In those who
have already failed the ﬁrst lines of the standard chemother-
apeutic regimens, even in the face of a signiﬁcant response
of the liver metastases, they ultimately have progression of
extrahepatic disease which will limit the survival. However,
as seen in this study and others, the toxicity proﬁle is
acceptable in those with limited systemic disease. Although
the beneﬁt may not be substantial in those with extrahepatic
disease, it is plausible to treat these patients since the liver is
typically the primary life-limiting factor.
Even in this cohort of chemorefractory patients, an
objective response to 90Y therapy was seen in a large pro-
portion of those patients who had follow-up data available.
A signiﬁcant biochemical response, CEA decrease by ≥50%,
was seen in 41% of patients. Although the median survival
was improved in those with a CEA response, this was not a
signiﬁcant diﬀerence. Jakobs et al. had reported a signiﬁcant
diﬀerence in survival for those with any decrease in CEA
with a median survival of 19.1months in responders versus
5.4months in nonresponders [19]. Kennedy et al. have also
reported a signiﬁcant diﬀerence in survival between those
who had an objective response, either biochemically or
radiographically [12]. The lack of signiﬁcance seen in our
study may be due to the larger number of patients with more
advanced disease in our sample.
When an objective radiographic response using RECIST
criteria was analyzed, 12.9% of patients had a partial
response and 64.5% of patients had stable disease. In other
similar retrospective studies the partial response was 17–
35.5%, stable disease was 55–61%, and progressive disease
was 9.8–10% [12, 19]. There was not a signiﬁcant diﬀerence
insurvivalassociatedwitharadiographicresponse.However,
it should be noted that follow-up imaging was available for
only31ofourpatientsandthuslimitsobjectiveradiographic
response analysis in this study.
The use of 90Y is shown to be well tolerated in patients
with advanced disease. The observed toxicities in this report
weresimilartothosenotedbyotherswithfatigue,abdominal
pain, and nausea the most frequent subjective complaints.
The incidence of these complaints was less than previously
reported. Sato et al. had reported the incidence of fatigue,
abdominal pain, and nausea to be 56%, 26%, and 23%,
respectively, compared to 22%, 16%, and 12% observed in
this cohort [15]. There were grade 2 bilirubin toxicities,
either early or late, seen in only 9 patients, and grade 3
and 4 toxicities were observed in only one patient each.
The pretreatment inclusion criteria of a total bilirubin level
of <2.0 is likely adequate to select patients with adequate
hepatic reserve to undergo treatment. Although there was
one incidence of an upper gastrointestinal bleed from
esophageal varices; soon after treatment we did not observe
the known complications of treatment-related peptic ulcers
and pneumonitis.
Our series has reinforced the ﬁndings of others. Mulcahy
et al. reported their single-institution series of 72 patients
using glass microspheres [26]. The treatment was well
toleratedinthesepatientswithself-limitedtreatment-related
toxicities of fatigue, abdominal pain, and nausea, 61%, 25%,
and 21%, respectively. Nine patients (12.6%) had grade 3 or
4 bilirubin toxicities. Using WHO criteria, a PR was noted
in 40.3%, SD in 44.5%, and PD in 14.8%. The median
time to PR was 4months with a time to hepatic progres-
sion of 15.4months. Survival analyses showed a median
survival of 14.5months from the time of initial treatment.
Favorable predictors of survival were radiographic response,
performance status, ≤25% tumor burden, and absence of
extrahepatic disease. The median survival was not aﬀected
by the chemotherapy received prior to 90Yt r e a t m e n t .
Several others have looked at the eﬃcacy and safety
of 90Y radioembolization combined with a radiosensitiz-
ing chemotherapy regimen as salvage therapy [27–29]. In
patients who had failed previous oxaliplatin- and irinotecan-
based therapy, in a series of 46 evaluable patients radio-
graphic response using RECIST criteria was CR in 2%,
PR in 22%, SD in 24%, and PD in 44% [27]. In another
recent publication, Ricke et al. published their phase I study
analyzing the eﬃcacy and safety of combining systemic
chemotherapy, using irinotecan, and 90Yt r e a t m e n tf o r
second-line therapy [28]. The combination therapy had
an acceptable toxicity proﬁle, not reaching the maximal
tolerated dose using up to 100mg/m2 of irinotecan on days
1 and 8 of a 3-week cycle. A large proportion of patients
had extrahepatic disease, 48%, and the site of ﬁrst disease
progression after treatment was extrahepatic in 57%. The
eﬃcacy was promising with either radiographically PR or
SD in 87% of patients. The median progression free survival
was 6.0months and progression free survival in the liver
was 9.2months. In yet another study, Van den Eynde et
al. performed a multicenter randomized controlled phase
III trial to assess the addition of 90Y resin microspheres to
continuous infusion of 5FU in 46 patients [29]. The median
time to liver progression was signiﬁcantly longer in patients
receiving RE compared with 5FU alone, 5.5, and 2.1months,
respectively.Themediansurvivalwas7.4monthsinthe5FU-
only arm and 9.9months in patients receiving 5FU plus 90Y.
This data leads us to question if patients with liver dominant
mCRC should have multimodality treatment with 90Ya n d
systemic chemotherapy earlier in the treatment algorithm.
It should be noted that the administration of 90Yf o r
mCRC is a complex process that requires a multidisciplinary
team. The cost of this process can be substantial. However,
we feel that this cost compares favorably to a course of
adjuvanttherapywithbiologicalagentssuchasbevacizumab.8 International Journal of Surgical Oncology
The treatments are generally well tolerated with the goal of
maintaining a high quality of life during therapy.
In conclusion, our report represents one of the larger
single-institution reports on the safety and eﬃcacy of 90Y
for chemorefractory patients with advanced liver-dominant
mCRC. We provide data to support the use of 90Y in the
salvage setting for patients after failing the latest chemother-
apeutic regimens evenin the presence of limited extrahepatic
disease. The use of 90Y to halt or slow the progression
of the hepatic tumor burden in patients with a terminal
disease process in an attempt to extend survival seems to be
achievable. The major limitations of this study is that it is
a retrospective study and although based in the setting of a
single-institution the patient population was heterogeneous
with most patients being referred to our tertiary center
from other institutions. We present evidence to suggest that
90Yi sa ne ﬀective and safe treatment option in the salvage
setting; however, there is still further validation required in
t h ef o r mo fp r o s p e c t i v et r i a l sw h i c ha r eo n g o i n g .I no r d e r
to convincingly support the beneﬁt gained with locoregional
therapy, progression free survival needs to be determined.
Overall survival is often suboptimal to determine beneﬁt
since progression of disease will often prompt alternative
treatments. Further work also needs to be done to evaluate
whether 90Y may have beneﬁt earlier in the treatment
algorithmpriortothesituationinwhichmost,ifnotallother
options are limited.
Conﬂict of Interests
None of the authors have identiﬁed a conﬂict of interests.
Acknowledgment
This work is supported by the NIH Roadmap Multidisci-
plinary Clinical Research Career Development Award Grants
(K12 HD04910 and NCI-5K07CA118576) from the National
Institute of Health.
References
[1] A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA
Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008.
[2] Y. Fong, N. Kemeny, P. Paty, L. H. Blumgart, and A. M. Cohen,
“Treatment of colorectal cancer: hepatic metastasis,” Seminars
in Surgical Oncology, vol. 12, no. 4, pp. 219–252, 1996.
[3] G.SteeleandT.S.Ravikumar,“Resectionofhepaticmetastases
from colorectal cancer: biologic perspectives,” Annals of
Surgery, vol. 210, no. 2, pp. 127–138, 1989.
[4] C. Breedis and G. Young, “The blood supply of neoplasms in
the liver,” The American journal of pathology, vol. 30, no. 5, pp.
969–977, 1954.
[5] A. S. Kennedy, C. Nutting, D. Coldwell, J. Gaiser, and C.
Drachenberg, “Pathologic response and microdosimetry of
90Y microspheres in man: review of four explanted whole
livers,” International Journal of Radiation Oncology Biology
Physics, vol. 60, no. 5, pp. 1552–1563, 2004.
[6] SIR-Spheres microspheres package insert. Sirtex Medi-
cal Inc., Wilmington, Mass, USA, 2009, http://www.sirtex
.com/ﬁles/US20Package20Insert1.pdf.
[7] TheraSphere Yttrium-90 Glass Microspheres. MDS Nor-
dion, Ottawa, Canada, 2009, http://www.mdsnordion.com/
therasphere/physicians-pack-age-insert/package-insert-us
.pdf.
[ 8 ]B .N .G r a y ,M .A .B u r t o n ,D .K .K e l l e h e r ,J .A n d e r s o n ,
and P. Klemp, “Selective internal radiation (SIR) therapy for
treatment of liver metastases: measurement of response rate,”
Journal of Surgical Oncology, vol. 42, no. 3, pp. 192–196, 1989.
[ 9 ]B .N .G r a y ,J .E .A n d e r s o n ,M .A .B u r t o ne ta l . ,“ R e g r e s s i o n
of liver metastases following treatment with yttrium-90
microspheres,” Australian and New Zealand Journal of Surgery,
vol. 62, no. 2, pp. 105–110, 1992.
[10] B. Gray, G. Van Hazel, M. Hope et al., “Randomised trial
of SIR-Spheres plus chemotherapy vs. chemotherapy alone
for treating patients with liver metastases from primary large
bowel cancer,” Annals of Oncology, vol. 12, no. 12, pp. 1711–
1720, 2001.
[11] G. Van Hazel, A. Blackwell, J. Anderson et al., “Randomised
phase 2 trial of SIR-spheres plus ﬂuorouracil/leucovorin
chemotherapy versus ﬂuorouracil/leucovorin chemotherapy
alone in advanced colorectal cancer,” Journal of Surgical
Oncology, vol. 88, no. 2, pp. 78–85, 2004.
[12] A. S. Kennedy, D. Coldwell, C. Nutting et al., “Resin 90Y-
microsphere brachytherapy for unresectable colorectal liver
metastases: modern USA experience,” International Journal of
RadiationOncologyBiologyPhysics,vol.65,no.2,pp.412–425,
2006.
[13] L. C. Lim, P. Gibbs, D. Yip et al., “A prospective evalua-
tion of treatment with selective internal radiation therapy
(SIR-spheres) in patients with unresectable liver metastases
from colorectal cancer previously treated with 5-FU based
chemotherapy,” BMC Cancer, vol. 5, article 132, 2005.
[14] L. Lim, P. Gibbs, D. Yip et al., “Prospective study of treatment
with selective internal radiation therapy spheres in patients
with unresectable primary or secondary hepatic malignan-
cies,” Internal Medicine Journal, vol. 35, no. 4, pp. 222–227,
2005.
[15] K. T. Sato, R. J. Lewandowski, M. F. Mulcahy et al., “Unre-
sectable chemorefractory liver metastases: radioembolization
with 90Y microspheres—safety, eﬃcacy, and survival,” Radiol-
ogy, vol. 247, no. 2, pp. 507–515, 2008.
[16] R. Mancini, L. Carpanese, R. Sciuto et al., “A multicentric
Phase II clinical trial on intra-arterial hepatic radiotherapy
with 90Yttrium SIR-spheres in unresectable, colorectal liver
metastasesrefractorytoi.v.chemotherapy:preliminaryresults
on toxicology and response rates,” In Vivo, vol. 20, pp. 711–
714, 2006.
[17] R. S. Stubbs, I. O’Brien, and M. M. Correia, “Selective internal
radiation therapy with 90Y microspheres for colorectal liver
metastases: single-centre experience with 100 patients,” ANZ
Journal of Surgery, vol. 76, no. 8, pp. 696–703, 2006.
[18] R. Murthy, H. Xiong, R. Nunez et al., “Yttrium 90 resin micro-
spheres for the treatment of unresectable colorectal hepatic
metastases after failure of multiple chemotherapy regimens:
preliminary results,” Journal of Vascular and Interventional
Radiology, vol. 16, no. 7, pp. 937–945, 2005.
[19] T.F.Jakobs,R.T.Hoﬀmann,K.Dehmetal.,“HepaticYttrium-
90 radioembolization of chemotherapy-refractory colorectal
cancer liver metastases,” Journal of Vascular and Interventional
Radiology, vol. 19, no. 8, pp. 1187–1195, 2008.
[20] H.Hurwitz,L.Fehrenbacher,W.Novotnyetal.,“Bevacizumab
plus irinotecan, ﬂuorouracil, and leucovorin for metastatic
colorectal cancer,” New England Journal of Medicine, vol. 350,
no. 23, pp. 2335–2342, 2004.International Journal of Surgical Oncology 9
[21] B. J. Giantonio, P. J. Catalano, N. J. Meropol et al., “Beva-
cizumab in combination with oxaliplatin, ﬂuorouracil, and
leucovorin (FOLFOX4) for previously treated metastatic col-
orectal cancer: results from the Eastern Cooperative Oncology
Group Study E3200,” Journal of Clinical Oncology, vol. 25, no.
12, pp. 1539–1544, 2007.
[22] R. Salem and K. G. Thurston, “Radioembolization with
90yttrium microspheres: a state-of-the-art brachytherapy
treatment for primary and secondary liver malignancies—
part 1: technical and methodologic considerations,” Journal of
Vascular and Interventional Radiology, vol. 17, no. 8, pp. 1251–
1278, 2006.
[23] A. Kennedy, S. Nag, R. Salem et al., “Recommendations for
radioembolization of hepatic malignancies using yttrium-90
microsphere brachytherapy: a consensus panel report from
the radioembolization brachytherapy oncology consortium,”
International Journal of Radiation Oncology Biology Physics,
vol. 68, no. 1, pp. 13–23, 2007.
[24] P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New
guidelines to evaluate the response to treatment in solid
tumors,” Journal of the National Cancer Institute, vol. 92, no.
3, pp. 205–216, 2000.
[25] R. S. Stubbs, R. J. Cannan, and A. W. Mitchell, “Selective
Internal Radiation Therapy with Yttrium Microspheres for
Extensive Colorectal Liver Metastases,” Journal of Gastroin-
testinal Surgery, vol. 5, no. 3, pp. 294–302, 2001.
[26] M. F. Mulcahy, R. J. Lewandowski, S. M. Ibrahim et al.,
“Radioembolization of colorectal hepatic metastases using
Yttrium-90 microspheres,” Cancer, vol. 115, no. 9, pp. 1849–
1858, 2009.
[27] M. Cosimelli, R. Mancini, and L. Carpanese, “Phase II multi-
center study of 90Yttrium resin microspheres for patients with
unresectable colorectal liver metastases who had failed prior
oxaliplatin- and irinotecan-based regimens,” in Proceedings of
the ASCO Gastrointestinal Cancers Symposium, 2009, Abstract
452.
[28] J. Ricke, R. R¨ uhl, M. Seidensticker et al., “Extensive liver-
dominant Colorectal (CRC) Metastases failing multiple lines
of systemic chemotherapy treated by 90Y Radioembolization:
a matched-pair analysis. 11th World Congress of GI Cancer,”
Annals of Oncology, vol. 20, supplement 6, 2009, Abstract PD-
002.
[29] M. Van den Eynde, A. Hendlisz, and M. Peeters, “Prospec-
tive randomized study comparing intraarterial injection of
yttrium-90 resin microspheres with protracted IV 5FU con-
tinuous infusion versus IV 5FU continuous infusion alone
for patients with liver-limited metastatic colorectal cancer
refractory to standard chemotherapy,” Journal of Clinical
Oncology,vol.27,supplement7,2009,ASCOAnnualMeeting,
abstract 4096.